Iradimed (IRMD) Cash from Financing Activities (2013 - 2026)

Iradimed (IRMD) has 14 years of Cash from Financing Activities data on file, last reported at -$2.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$2.6 million, down 14.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.9 million (down 109.11% YoY), and the FY2025 annual result was -$17.6 million, down 22.77% from the prior year.
• Cash from Financing Activities climbed to -$2.6 million in Q1 2026 per IRMD's latest filing, from -$10.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $52341.0 in Q3 2022 and troughed at -$13.3 million in Q1 2023.
• A 5-year average of -$3.6 million and a median of -$2.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 34536.13% in 2022, then jumped 71.67% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$198457.0 in 2022, then tumbled by 32.32% to -$262590.0 in 2023, then tumbled by 820.64% to -$2.4 million in 2024, then sank by 349.78% to -$10.9 million in 2025, then jumped by 76.03% to -$2.6 million in 2026.
• Business Quant data shows IRMD's Cash from Financing Activities at -$2.6 million in Q1 2026, -$10.9 million in Q4 2025, and -$2.2 million in Q3 2025.